Reports Q3 revenue $17.63M, consensus $18.85M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “Our third quarter 2025 results reflect continued strong execution and accelerating commercial momentum, with revenue increasing 21% year-over-year to $17.6 million. Emrosi(TM) continues to drive growth, generating $4.9 million in net sales in the third quarter alone, supported by robust market adoption and payer access that continues to expand. We anticipate the growth of Emrosi and our established dermatology commercial infrastructure to generate significant operating leverage going forward.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: